© 2016, Bayer AS
Siste oppdatering 08 april 2016
L.NO.MKT.03.2016.1478

Publications

For General Physicians

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study
Circulation 2007;116(2):180–187

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement
Circulation 2006;114:2374–2381

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
Thromb Haemost 2007;97:931–937

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Haas S. Rivaroxaban
an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
J Clin Pharmacol 2007;47:218–226

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Maclaine G, Wild D, Reaney M
Patient satisfaction with long-term warfarin for the treatment and secondary prevention of venous thromboembolism.
Pathophysiol Haemost Thromb 2006;35 (1–2):A44

Murray M, Friedman H
A retrospective study of current anticoagulant use in patients with atrial fibrillation: results from a managed care database.
Blood 2005;106(11):Abstract 2246

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabant A
An in vivo risk–benefit comparison of the effects of rivaroxaban – an oral, direct Factor Xa inhibitor – with thrombin inhibitors, warfarin and clopidogrel.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-638

Perzborn E, Harwardt M
Recombinant Factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-640

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis.
Blood (ASH Annual Meeting Abstracts) 2008;112:3031

Walenga JM, Hoppensteadt D, Iqbal O, Neville B, Jeske W, Prechel M, Messmore HL, Misselwitz F, Bakhos M
The oral, direct Factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin/PF4 (heparin-induced thrombocytopenia) antibodies.
Blood 2005;106:Abstract 1883

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

For Surgeons

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Borris LC.
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Thromb Res 2007;120(5):685–693

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement
Circulation 2006;114:2374–2381

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E.
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates.
Blood (ASH Annual Meeting Abstracts) 2008;112:3825

Haas S. Rivaroxaban
an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Kwong LM
Rivaroxaban, an oral, direct Factor Xa inhibitor: a new option for thromboprophylaxis
Orthopedics 2009; in press

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG
Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Arterioscler Thromb Vasc Biol 2007;27(6):1238–1247

Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M, for the ODIXa-KNEE Study Group
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
J Thromb Haemost 2005;3:2479–2486

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

For Hematologists

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study
Circulation 2007;116(2):180–187

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Thromb Res 2007;120(5):685–693

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement
Circulation 2006;114:2374–2381

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Haas S. Rivaroxaban
an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin.
J Clin Pharmacol 2006;46:981–990

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Co-administration of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and clopidogrel in healthy subjects
Eur Heart J 2007;28(Suppl. 1):189

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
J Clin Pharmacol 2007;47:218–226

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG
Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery
Clin Pharmacokinet 2008:47(3);203–216

Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A.
Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban
Eur Heart J 2008;29(Abstract Supplement):825

Perzborn E, Harwardt M.
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin–Protein C System.
Blood (ASH Annual Meeting Abstracts) 2008;112:528

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Smith SA, Morrissey JH
Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors
Blood 2007;110(11):Abstract 928

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG
Warfarin replacements: mechanisms underlying emerging agents
Can J Cardiol 2008;24:56–60

Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M, for the ODIXa-KNEE Study Group
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
J Thromb Haemost 2005;3:2479–2486

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis.
Blood (ASH Annual Meeting Abstracts) 2008;112:3031

Walenga JM, Hoppensteadt D, Iqbal O, Neville B, Jeske W, Prechel M, Messmore HL, Misselwitz F, Bakhos M
The oral, direct Factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin/PF4 (heparin-induced thrombocytopenia) antibodies.
Blood 2005;106:Abstract 1883

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

For Pharmacists

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study
Circulation 2007;116(2):180–187

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Kakar P, Watson T, Lip GY
Rivaroxaban.
Drugs Today 2007;43:129–136

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral direct Factor Xa inhibitor.
Blood 2006;108:Abstract 905

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
J Clin Pharmacol 2007;47:218–226

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Maclaine G, Wild D, Reaney M
Patient satisfaction with long-term warfarin for the treatment and secondary prevention of venous thromboembolism.
Pathophysiol Haemost Thromb 2006;35 (1–2):A44

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008;100:453-61.

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Walenga JM, Hoppensteadt D, Iqbal O, Neville B, Jeske W, Prechel M, Messmore HL, Misselwitz F, Bakhos M
The oral, direct Factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin/PF4 (heparin-induced thrombocytopenia) antibodies.
Blood 2005;106:Abstract 1883

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

For Cardiologists

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study
Circulation 2007;116(2):180–187

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study
Blood 2008;112:2242-2247

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
N Engl J Med 2008;358:2765–2775

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
Thromb Haemost 2007;97:931–937

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Haas S. Rivaroxaban
an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral direct Factor Xa inhibitor.
Blood 2006;108:Abstract 905

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin
J Clin Pharmacol 2006; 46(6):702

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Kubitza D, Mueck W, Becka M. Randomized
Double-blind, crossover study to investigate the effect of rivaroxaban on T-interval prolongation
Drug Saf 2008;31(1):67–77

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Maclaine G, Wild D, Reaney M
Patient satisfaction with long-term warfarin for the treatment and secondary prevention of venous thromboembolism.
Pathophysiol Haemost Thromb 2006;35 (1–2):A44

Murray M, Friedman H
A retrospective study of current anticoagulant use in patients with atrial fibrillation: results from a managed care database.
Blood 2005;106(11):Abstract 2246

Murray M, Wild D, Reaney M
Exploring patient satisfaction with long-term warfarin for the treatment of atrial fibrillation.
Blood 2005;106(11):Abstract 2245

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabant A
An in vivo risk–benefit comparison of the effects of rivaroxaban – an oral, direct Factor Xa inhibitor – with thrombin inhibitors, warfarin and clopidogrel.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-638

Perzborn E, Fischer E, Lange U
Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats
Eur Heart J 2007;28(Suppl. 1):189

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG
New oral anticoagulants in atrial fibrillation.
Eur Heart J 2008;29(2):155–165

Turpie AGG
New oral anticoagulants in atrial fibrillation
Eur Heart J 2008;29(2):155–165

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

All

Abrams PJ, Emerson CR.
Rivaroxaban: a novel, oral, direct factor xa inhibitor.
Pharmacotherapy 2009 29:167-81

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study
Circulation 2007;116(2):180–187

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S
for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) Study
Circulation 2007;116(2):180–187

Bauer K, Homering M, Berkowitz S.
Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery.
Blood (ASH Annual Meeting Abstracts) 2008;112:436

Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor
Thromb Haemost 2007;97:471–477

Borah B, McDonald H, Henk J, Crowther M, Selby R, Wells P.
Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients.
Blood (ASH Annual Meeting Abstracts) 2008;112:170

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F
Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events
J Thromb Haemos 2008 Aug 1 [Epub ahead of print]

Borris LC.
Barriers to the optimal use of anticoagulants after orthopaedic surgery.
Arch Orthop Trauma Surg 2008 Oct 8. [Epub ahead of print]

Borris LC.
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62

Büller HR, Agnelli G
Treatment of proximal deep vein thrombosis (DVT): Rivaroxaban once or twice daily had similar efficacy and safety to standard therapy in phase II studies
J Thromb Haemost 2007; 5 (Suppl 2):Abstract O-W-052

Büller HR, Agnelli G, Lensing AWA, Misselwitz F, the EINSTEIN-DVT and ODIXa-DVT Study groups
Rivaroxaban once or twice daily: similar efficacy and safety to standard therapy in dose-ranging studies for the treatment of proximal deep vein thrombosis
J Am Coll Cardiol 2007;49:364A

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study
Blood 2008;112:2242-2247

Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008;112:2242-2247

Chaplin S
Rivaroxaban: a new orally active direct inhibitor of Factor Xa
Future Prescriber 2008;9:11–19

Diamantopoulos A, Forster F, Brosa M, Lees M, Gilmour L, Ashley D, Piñol C.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Brosa M, Lees M, Piñol C, Febrer L.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Spain.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Lees M, Gilmour L, Ashley D.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK.
Value Health 2008;11:A362-A659

Diamantopoulos A, Forster F, Lees M, McDonald H.
Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Canada.
Value Health 2008;11:A362-A659

Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M, Wells P.
Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.
Blood (ASH Annual Meeting Abstracts) 2008;112:1292

Eriksson B, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee arthroplasty
J Bone Joint Surg 2009 in press

Eriksson B, Turpie A, Lassen M, Kakkar A, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.
Blood (ASH Annual Meeting Abstracts) 2008;112:1986

Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, for the ODIXa-HIP Study Investigators
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
J Thromb Haemost 2006;4:121–128

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
Thromb Res 2007;120(5):685–693

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement
Circulation 2006;114:2374–2381

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. (sign-in required to view article )
N Engl J Med 2008;358:2765–2775

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
N Engl J Med 2008;358:2765–2775

Filippi A, Alacqua M, Shakespeare A, Mazzaglia G, Bianchi C, Cowell W, Cricelli C.
Management of atrial fibrillation with oral anticoagulants and predictors in clinical practice in Italy.
Eur Heart J 2008;29(Abstract Supplement):534

Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
Thromb Haemost 2007;97:931–937

Friedman R, Lees M, Sengupta N, Haas S
Rivaroxaban for prevention of venous thromboembolism after total hip replacement: impact on healthcare costs based on the RECORD1 study
J Bone Joint Surg Br

Gerotziafas GT, Elalamy I, Perzborn E, Depasse F, Samama MM
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban
J Thromb Haemost 2007;5:886–888

Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A,  Markov V, Burton P, Braunwald E.
Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial.
Circulation 2008;118:2311

Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S
Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
J Clin Pharmacol 2007;47:1398–1407

Gruber A, Marzec U, Buetehorn U, Hanson S, Perzborn E.
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates.
Blood (ASH Annual Meeting Abstracts) 2008;112:3825

Gruber A, Marzec UM, Buetehorn U, Hanson SR, Perzborn E
Recombinant Factor VIIa reverses the effects of a high dose of rivaroxaban in baboons
Pathophysiol Haemost Thromb 2007/2008;36:A39

Gulseth MP, Michaud J, Nutescu EA
Rivaroxaban: an oral direct inhibitor of factor Xa
Am J Health Syst Pharm 2008;65:1520-9

Haas S. Rivaroxaban
an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme
Eur J Haematol 2009 Jan 29;82(5):339-349

Haertlein B, Parry TJ, Chen C, Perzborn E, Andrade-Gordon P, Damiano BP
Rivaroxaban An Oral, Direct Factor Xa Inhibitor Prevents Arterial Thrombotic Occlusion in Electrolytically Injured Rat Carotid Arteries
Blood 2007;110(11):Abstract: 3-a-4003

Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk A
Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-M-635

Halabi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Schafers R, Wand D, Philipp T, Bruck H
Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor.
Blood 2006;108:Abstract 913

Hoppensteadt D, Neville B, Cunanan J, Maddenini J, Perzborn E, Misselwitz F, Fareed J
Comparison of the anticoagulant properties of BAY 59-7939 – an oral, direct Factor Xa inhibitor – with fondaparinux and enoxaparin
J Thromb Haemost 2005;3(Suppl 1):Abstract P1120

Hoppensteadt D, Neville B, Schultz C, Cunanan J, Duff R, Perzborn E, Misselwitz F, Fareed J
Interaction of BAY 59-7939 – a novel, oral, direct Factor Xa inhibitor – with antiplatelet agents: monitoring and therapeutic applications
J Thromb Haemost 2005;3(Suppl 1):Abstract P1717

Kakar P, Watson T, Lip GY
Drug evaluation: Rivaroxaban, an oral, direct inhibitor of activated Factor X
Curr Opin Investig Drugs 2007;8:256–265

Kakar P, Watson T, Lip GY
Rivaroxaban.
Drugs Today 2007;43:129–136

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz, F, Haas S
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet 2008;372:31–39

Kakkar AK, Lees M, Sengupta N, Muntz J
Prevention of venous thromboembolism with rivaroxaban after total hip replacement: economic impact of extended thromboprophylaxis
J Bone Joint Surg Br; in press

Kamphuisen PW.
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty.
ACP J Club. 2008 Nov-Dec;149(4):6-7.

Klein M, Perzborn E, Laux V, Schäfer S, von Degenfeld G.
The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats.
Eur Heart J 2008;29(Abstract Supplement):564

Komotar RJ, Starke RM, Connolly ES Jr.
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Neurosurgery 2008 Oct;63:N10-11

Kubitza D, Becka M, Mueck W, Zuehlsdorf
Pharmacology of the oral, direct Factor Xa inhibitor rivaroxaban – effect of extreme age and gender.
Hämostaseologie 2007;27:A40

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59–7939 – An Oral, Direct Factor Xa Inhibitor
J Thromb Haemost 2005; Volume 3, Supplement 1: P1105

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
Br J Clin Pharmacol 2007;63:469–476

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin.
J Clin Pharmacol 2006;46:981–990

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral direct Factor Xa inhibitor.
Blood 2006;108:Abstract 905

Kubitza D, Becka M, Mueck W, Zuehlsdorf M
Co-administration of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and clopidogrel in healthy subjects
Eur Heart J 2007;28(Suppl. 1):189

Kubitza D, Becka M, Voith B, Zuehlsdorf M
Effect of enoxaparin on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor
J Thromb Haemost 2005;3(Suppl 1):Abstract P1704

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
Clin Pharmacol Ther 2005;78:412–421

Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M
Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects.
Eur J Clin Pharmacol2005;61:873–880

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
J Clin Pharmacol 2006;46:549–558

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin
J Clin Pharmacol 2006; 46(6):702

Kubitza D, Becka M, Zuehlsdorf M, Mueck W
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
J Clin Pharmacol 2007;47:218–226

Kubitza D, Haas S
Novel Factor Xa inhibitors for prevention and treatment of thromboembolic disease.
Expert Opin Investig Drugs 2006;15:843–855

Kubitza D, Mueck W, Becka M
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Drug Saf 2008;31(1):67–77

Kubitza D, Mueck W, Becka M
No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor- and atorvastatin.
Pathophysiol Haemost Thromb 2007/2008;36:A40

Kubitza D, Mueck W, Becka M. Randomized
Double-blind, crossover study to investigate the effect of rivaroxaban on T-interval prolongation
Drug Saf 2008;31(1):67–77

Kwong L, Diamantopoulos A, Forster F, Sengupta N, Lees M.
Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients?
Blood (ASH Annual Meeting Abstracts) 2008;112:1290

Kwong L, Lees M, Sengupta N
Rivaroxaban for prevention of venous thromboembolism after total knee arthroplasty: impact on healthcare costs based on the RECORD3 study
Blood 2007;110(11):Abstract 1874

Kwong L, Sengupta N, Lees M.
Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study.
Blood (ASH Annual Meeting Abstracts) 2008;112:1289

Kwong LM
Rivaroxaban, an oral, direct Factor Xa inhibitor: a new option for thromboprophylaxis
Orthopedics 2009; in press

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG
Rivaroxaban for thromboprophylaxis after total knee arthroplasty
N Engl J Med 2008;358: 2776–2785

Laux V, Perzborn E, Kubitza D, Misselwitz F
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct Factor Xa inhibitor.
Semin Thromb Haemost 2007;33(5):515–523

Maclaine G, Wild D, Reaney M
Patient satisfaction with long-term warfarin for the treatment and secondary prevention of venous thromboembolism.
Pathophysiol Haemost Thromb 2006;35 (1–2):A44

Mueck W, Agnelli G, Büller H, (Intr by Misselwitz F)
Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT)
Blood 2007;110(11):Abstract 1880

Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy subjects
Int J Clin Pharm Ther 2007;45:335–344

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008;100:453-61.

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AGG
Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery
Clin Pharmacokinet 2008:47(3);203–216

Mueck W, Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muehlhofer E, Misselwitz F
Rivaroxaban for thromboprophylaxis in patients undergoing total hip replacement: comparison of pharmacokinetics and pharmacodynamics with once- and twice-daily dosing
Blood 2006;108:Abstract 903

Murray M, Friedman H
A retrospective study of current anticoagulant use in patients with atrial fibrillation: results from a managed care database.
Blood 2005;106(11):Abstract 2246

Murray M, Wild D, Reaney M
Exploring patient satisfaction with long-term warfarin for the treatment of atrial fibrillation.
Blood 2005;106(11):Abstract 2245

Paramanathan V.
Rivaroxaban: future in anticoagulation practice?
Hematology. 2008 Oct;13(5):257-60.

Perzborn E, Arndt B
Antithrombotic effects of concomitant administration of BAY 59-7939 with enoxaparin or heparin – interaction study
Blood 2004;104:Abstract 1863

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabandt A
Antithrombotic effects of rivaroxaban – an oral, direct Factor Xa inhibitor – in animal models of arterial and venous thrombosis: comparison with enoxaparin, an antithrombin-dependent anticoagulant
Eur Heart J 2006;27(Abstract Suppl):762

Perzborn E, Arndt B, Fischer E, Harwardt M, Lange U, Trabant A
An in vivo risk–benefit comparison of the effects of rivaroxaban – an oral, direct Factor Xa inhibitor – with thrombin inhibitors, warfarin and clopidogrel.
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-638

Perzborn E, Arndt B, Harward M, Trabandt A
Antithrombotic efficacy of BAY 59-7939 – an oral, direct Factor Xa inhibitor – compared with fondaparinux in animal arterial thrombosis and thromboembolic death models
Eur Heart J 2005;26(Abstract Suppl):481

Perzborn E, Buetehorn U, Fischer E, Harwardt M, Klages M, Trabandt A.
Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran , but is reduced by the direct factor Xa inhibitor rivaroxaban
Eur Heart J 2008;29(Abstract Supplement):825

Perzborn E, Fischer E, Lange U
Rivaroxaban – a novel, oral, direct Factor Xa inhibitor – enhanced the antithrombotic effects of clopidogrel in rats
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-641

Perzborn E, Fischer E, Lange U
Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats
Eur Heart J 2007;28(Suppl. 1):189

Perzborn E, Fischer E, Lange U
Combining rivaroxaban with acetylsalicylic acid increases antithrombotic potency without affecting bleeding times in animal models
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-639

Perzborn E, Harwardt M
Recombinant Factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-640

Perzborn E, Harwardt M.
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin–Protein C System.
Blood (ASH Annual Meeting Abstracts) 2008;112:528

Perzborn E, Hirth-Dietrich C, Fischer E, Groth M, Hartmann E, Sperlich-Wulf K (Intr by Misselwitz F)
Rivaroxaban has protective effects in a model of disseminated intravascular coagulation (DIC) in rats
Blood 2007;110(11):Abstract 935

Perzborn E, Kubitza D, Misselwitz F
Rivaroxaban - A novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders
Hämostaseologie 2007;27(4):282–289

Perzborn E, Lange U
Rivaroxaban – an oral, direct Factor Xa inhibitor – inhibits tissue factor-mediated platelet aggregation
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-642

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor.
J Thromb Haemost 2005;3:514–521

Perzborn E, Tinel H
FEIBA reverses the effects of a high dose of rivaroxaban in rats
Pathophysiol Haemost Thromb 2007/2008;36:A40

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM
Rivaroxaban, an oral direct Factor Xa inhibitor
Expert Opin Investig Drugs 2008;17:925–937

Pleiss U, Seidel D, Grosser R
Syntheses of [14C]BAY 59-7939 and its radiolabeled metabolite M-4
J Labelled Compd Rad 2006;49:929–934

ROCKET AF Executive Committee, Nessel C, Hacke W. Rivaroxaban
Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Ongoing Clinical Trials Posters 2009

Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer K-H, Reinemer P, Perzborn E
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor
J Med Chem 2005;48:5900–5908

Rohde G
Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
J Chromatogr B Analyt Technol Biomed Life Sci 2008 Jul 23 [Epub ahead of print]

Samama M, Le Flem L, Guinet C, Perzborn E, Martinoli JL, Depasse F.
Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays.
Blood (ASH Annual Meeting Abstracts) 2008;112:3028

Samama MM, Le Flem L, Guinet C, Perzborn E, Depasse F
Measuring rivaroxaban pharmacodynamics: prothrombinase induced clotting time (PiCT®) and Heptest®
Pathophysiol Haemost Thromb 2008;36(suppl 1):A68 ABSTR P174

Samama MM, Le Flem L, Guinet C, Perzborn E, Martinoli JL, Depasse F
Effects of rivaroxaban and fondaparinux on clotting assays
Pathophysiol Haemost Thromb 2008;36(suppl 1):A68 ABSTR P173

Schellong SM, Beyer J, Kakkar AK, Halbritter K, Eriksson BI, Turpie Ag, Misselwitz F, Kalebo O
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
J Thromb Haemost 2007;5(7):1431–1437

Smith SA, Morrissey JH
Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors
Blood 2007;110(11):Abstract 928

Tersteegen A, Burkhardt N
Rivaroxaban – an oral, direct Factor Xa inhibitor – binds rapidly to Factor Xa
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-651

Tinel H, Huetter J, Perzborn E
Recombinant Factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in rats
J Thromb Haemost 2007;5(Suppl 2):Abstract P-W-652

Tinel H, Huetter J, Perzborn E
Partial reversal of the anticoagulant effect of high-dose rivaroxaban – an oral, direct Factor Xa inhibitor – by recombinant Factor VIIa in rats.
Blood 2006;108:Abstract 915

Turpie A, Bauer K, Davidson B, Gent M, Kwong L, Lassen M, Cushner F, Lotke P, Berkowitz S, Bandel T-J, Misselwitz F, Fisher W.
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4.
Blood (ASH Annual Meeting Abstracts) 2008;112:35

Turpie A, Lassen M, Kakkar A, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M.
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding.
Blood (ASH Annual Meeting Abstracts) 2008;112:36

Turpie AGG
New anticoagulant drugs in venous and arterial thrombosis
Haematologica Reports 2006; 2(4):10–11

Turpie AGG
New oral anticoagulants in atrial fibrillation.
Eur Heart J 2008;29(2):155–165

Turpie AGG
New oral anticoagulants in atrial fibrillation
Eur Heart J 2008;29(2):155–165

Turpie AGG
Warfarin replacements: mechanisms underlying emerging agents
Can J Cardiol 2008;24:56–60

Turpie AGG
Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Arterioscler Thromb Vasc Biol 2007;27(6):1238–1247

Turpie AGG, Bauer KA, Davidson BL, Gent M, Kwong LM, Lassen MR, Cushner FD, Lotke PA, Bandel TJ, Misselwitz F, Fisher WD
Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study)
J Bone Joint Surg Br; in press

Turpie AGG, Eriksson BI, Mueck W, Bauer KA, Borris LC, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F
Pharmacokinetic and pharmacodynamic analyses of rivaroxaban in patients undergoing orthopaedic surgery
Pathophysiol Haemost Thromb 2006;35(1–2):A2

Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M, for the ODIXa-KNEE Study Group
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
J Thromb Haemost 2005;3:2479–2486

Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M
A meta-analysis of three pivotal studies of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – for thromboprophylaxis after orthopaedic surgery
Pathophysiol Haemost Thromb 2008;36(suppl 1):A15 ABSTR O57

Varin R, Mirshahi S, Mirshahi P, Lu-Hong L, Kierzek G, Vigneau JF, Marie J-P, Perzborn E, Mirshahi M, Soria C, Soria J.
Improvement of Thrombolysis by Rivaroxaban, an Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis.
Blood (ASH Annual Meeting Abstracts) 2008;112:3031

Walenga JM, Hoppensteadt D, Iqbal O, Neville B, Jeske W, Prechel M, Messmore HL, Misselwitz F, Bakhos M
The oral, direct Factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin/PF4 (heparin-induced thrombocytopenia) antibodies.
Blood 2005;106:Abstract 1883

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M.
Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia
Br J Haem 2008;143:92-9.

Weinz C, Buetehorn U, Daehler H-P, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W
Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
Xenobiotica 2005;35:891–910

Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U
In vitro metabolism of BAY 59-7939 – an oral, direct Factor Xa inhibitor
Drug Metab Rev 2004;36(Suppl 1):Abstract 195

Weinz C, Schwarz T, Pleiss U, Shmeer K, Kubitza D, Mueck W, Gondol D, Aitken H
Metabolism and distribution of [14C]BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rat, dog, and human
Drug Metab Rev 2004;36(Suppl 1):Abstract 196

Wells P, Diamantopoulos A, Forster F, Lees M, McDonald H.
Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.
Blood (ASH Annual Meeting Abstracts) 2008;112:1291

Wild D, Murray M, Shakespeare A, Reaney M, von Maltzahn R
Patient-reported treatment satisfaction measures for long-term anticoagulant therapy
Expert Review of Pharmacoeconomics & Outcomes Research 2008;8:291-299